- Home
- SWIM vs ZYME Comparison
SWIM vs ZYME Comparison
Compare SWIM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- ZYME
- Stock Information
- Founded
- SWIM 1956
- ZYME 2003
- Country
- SWIM United States
- ZYME United States
- Employees
- SWIM N/A
- ZYME N/A
- Industry
- SWIM Plastic Products
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- ZYME Health Care
- Exchange
- SWIM Nasdaq
- ZYME Nasdaq
- Market Cap
- SWIM 751.3M
- ZYME 751.6M
- IPO Year
- SWIM 2021
- ZYME 2017
- Fundamental
- Price
- SWIM $5.72
- ZYME $15.39
- Analyst Decision
- SWIM Hold
- ZYME Buy
- Analyst Count
- SWIM 5
- ZYME 5
- Target Price
- SWIM $5.62
- ZYME $19.00
- AVG Volume (30 Days)
- SWIM 695.0K
- ZYME 572.6K
- Earning Date
- SWIM 11-05-2024
- ZYME 10-31-2024
- Dividend Yield
- SWIM N/A
- ZYME N/A
- EPS Growth
- SWIM N/A
- ZYME N/A
- EPS
- SWIM 0.10
- ZYME N/A
- Revenue
- SWIM $512,114,000.00
- ZYME $62,199,000.00
- Revenue This Year
- SWIM N/A
- ZYME $30.09
- Revenue Next Year
- SWIM $5.14
- ZYME N/A
- P/E Ratio
- SWIM $57.51
- ZYME N/A
- Revenue Growth
- SWIM N/A
- ZYME N/A
- 52 Week Low
- SWIM $2.11
- ZYME $7.80
- 52 Week High
- SWIM $7.33
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- SWIM 39.61
- ZYME 55.74
- Support Level
- SWIM $5.40
- ZYME $12.39
- Resistance Level
- SWIM $6.16
- ZYME $17.70
- Average True Range (ATR)
- SWIM 0.34
- ZYME 0.84
- MACD
- SWIM -0.09
- ZYME 0.10
- Stochastic Oscillator
- SWIM 24.32
- ZYME 56.50
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.